David Shaw’s NovoCure NVCR Stock Holding History

David Shaw’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,200	Closed	-$196K	–	4877
2025 Q3	$196K	Buy	+15,200	New	+$203K	﹤0.01%	4289
2025 Q1	–	Sell	-66,700	Closed	-$1.99M	–	4589
2024 Q4	$1.99M	Hold	66,700	–	–	﹤0.01%	2740
2024 Q3	$1.04M	Hold	66,700	–	–	﹤0.01%	3245
2024 Q2	$1.14M	Buy	66,700 +25,400	+62%	+$447K	﹤0.01%	3097
2024 Q1	$646K	Buy	+41,300	New	+$607K	﹤0.01%	3358
2022 Q2	–	Sell	-10,000	Closed	-$829K	–	5631
2022 Q1	$829K	Sell	10,000 -30,000	-75%	-$2.21M	﹤0.01%	4052
2021 Q4	$3M	Hold	40,000	–	–	﹤0.01%	2954
2021 Q3	$4.65M	Buy	40,000 +10,000	+33%	+$1.51M	﹤0.01%	2167
2021 Q2	$6.66M	Buy	30,000 +20,000	+200%	+$3.89M	0.01%	1813
2021 Q1	$1.32M	Sell	10,000 -9,500	-49%	-$1.5M	﹤0.01%	2900
2020 Q4	$3.37M	Buy	+19,500	New	+$2.67M	﹤0.01%	2177
2020 Q3	–	Sell	-19,100	Closed	-$1.13M	–	4052
2020 Q2	$1.13M	Sell	19,100 -10,900	-36%	-$717K	﹤0.01%	2834
2020 Q1	$2.02M	Buy	30,000 +12,600	+72%	+$996K	﹤0.01%	2154
2019 Q4	$1.47M	Hold	17,400	–	–	﹤0.01%	2718
2019 Q3	$1.3M	Buy	+17,400	New	+$1.39M	﹤0.01%	2669
2019 Q2	–	Sell	-20,000	Closed	-$963K	–	3800
2019 Q1	$963K	Buy	+20,000	New	+$963K	﹤0.01%	2629

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

David Shaw's NVCR Position: Q2 2026 in Review

David Shaw increased its NovoCure (NVCR) stake by 58% in Q2 2026, buying an estimated $5.68M and bringing the position to 1,022,480 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1482.

David Shaw first reported a position in NVCR in Q4 2016 and has held it in 33 quarters since. The position peaked at $34.6M in Q2 2019. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

David Shaw held 1,022,480 shares of NovoCure worth $15.5M as of Q2 2026.
David Shaw bought 375,418 NovoCure shares in Q2 2026, an estimated $5.68M.
NovoCure made up 0.01% of David Shaw's portfolio in Q2 2026, its #1482 holding.
David Shaw first reported a position in NovoCure in Q4 2016 and has held it in 33 quarters since.
David Shaw's NovoCure position peaked at $34.6M in Q2 2019.
215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.